Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.78
-0.0400-0.25%
Volume:3.43M
Turnover:54.16M
Market Cap:3.18B
PE:-19.09
High:15.96
Open:15.93
Low:15.65
Close:15.82
52wk High:15.97
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.88
T/O Rate:1.75%
Dividend:1
Dividend Rate:6.34%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.03
PE(LYR):-11.03

Loading ...

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

GlobeNewswire
·
Apr 30

Thirteen Individuals Detained for Orchestrating Vulgar Online Streaming "Showdown" Competitions

Deep News
·
Apr 30

Park Hotels & Resorts Inc expected to post earnings of 3 cents a share - Earnings Preview

Reuters
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

Park Hotels & Resorts shareholders elect nine directors at annual meeting

Reuters
·
Apr 28

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GlobeNewswire
·
Apr 28

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

GlobeNewswire
·
Apr 27

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

GlobeNewswire
·
Apr 27

Hilton plans 15 new hotels in Morocco to double portfolio to 25 properties

Reuters
·
Apr 24

Earning Preview: Park Hotels & Resorts Inc. this quarter’s revenue is expected to decrease by 0.21%, and institutional views are bearish

Earnings Agent
·
Apr 24

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

GlobeNewswire
·
Apr 23

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Dow Jones
·
Apr 23

Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform

GlobeNewswire
·
Apr 22

LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study

Stock News
·
Apr 20

Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015

TIPRANKS
·
Apr 20

Comparison of Major Brokerages' Overseas Expansion: Who Leads the Pack?

Deep News
·
Apr 13

ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406

prnewswire
·
Apr 10

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

GlobeNewswire
·
Apr 08

Comparison of Trading Platforms for Novice Fund Investors: Three Leading Apps Recommended

Deep News
·
Apr 08

Park Hotels & Resorts Cut to Equal-Weight From Overweight by Barclays

Dow Jones
·
Apr 07